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Purpose/Objective: Pulmonary seed emboli to the chest may 
occur following permanent prostate brachytherapy (PPB). We 
have reviewed our institutional experience of seed migration 
after PPB comparing loose seeds (LS), mixed loose and 
stranded seeds (MLS), and stranded seeds in an absorbable 
vicryl suture (VS)  
Materials and Methods: Between May 1998 and June 2014, 
1,133 patients underwent PPB at our institution. A total of 
990 consecutive patients with postoperative diagnostic chest 
x-rays were reviewed for analysis of seed migration. Patients 
were grouped based on the type of seed modality implanted: 
LS=397 (40.1%), MS= 46 (4.6%), and VS=547 (55.3%) patients. 
Mick applicator was most frequently used for LS placement. I-
125 and Pd-103 seeds were used in 976 (98.6%) and 14 (1.4%) 
patients, respectively. The mean number of days to chest X-
ray was 109 days (IQR range, 105-149). Pairwise comparison 
was used to determine statistical significance.  
Results: The mean prostate volume and number of seeds 
implanted in each group was 39.9 cc (range, 8-98) and 116 
seeds (range, 49-214), 37.8 cc (range, 17.5-75) and 93.2 
seeds (range, 62-145), and 36.8 cc (range, 13.5-77) and 77.9 
seeds (range, 44-116) for LS, MS, and VS, respectively. The 
overall rate of seed migration was 0.38% (351/93,230). The 
rate of seed migration per group was 0.73% (339/46,346) for 
LS, 0.16% (7/4,288) for MS, and 0.012% (5/42,596) for VS. The 
percent of patients with seed migration and the mean 
number of migrated seeds per patient was 45% and 1.9 seeds 
(range, 1-10) 13% and 1.2 seeds (range, 1-2), and 0.9% and 1 
seed (range, 1), for LS, MS, and VS, respectively. The right 
and left lower lobe were the most frequent sites of 
pulmonary seed migration. Pairwise comparison showed a 
significantly higher rate of seed migration in the LS group 
compared to the MLS (p<0.001) and VS group (p<0.001). 
Patients treated with any number of loose seeds had a 
significantly higher rate of seed migration than patients with 
completely stranded seed implants (p<0.001). 
Conclusions: Our results demonstrate a significantly higher 
rate of seed migration to the chest with use of loose seeds 
compared to stranded seeds. Our results are consistent with 
previous retrospective series and a single prospective study. 
In addition, the present study also provides rates of seed 
migration for mixed loose and stranded implants. Rates of 
seed migration are lowest when 100% of seeds are placed 
using stranded seed material.  
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Purpose/Objective: To investigate the long-term outcome 
for patients treated with high dose-rate brachytherapy (HDR 
BT) in combination with external beam therapy in the years 
2004 to 2005. 5 and 8 year outcome data are presented. 
Materials and Methods: Conformal external beam therapy 
(50 Gy to the pelvis, 40 Gy to the prostate) was delivered in 
combination with two fractions HDR brachytherapy (BT) 
(delta=two weeks) of 15 Gy to the peripheral zone of the 
prostate. A cohort of 80 patients was investigated, treated 
between June 2004 and August 2005 in our clinic. Patient 
mean age was 68.2 years (SD: 5.2). We had 7.5% T1, 62.5% T2 
(17.5% T2a, 27.5% T2b, 17.5% T2c), and 30.0% T3 tumors in 
our study group. 42 of the 80 patients underwent 
antihormonal deprivation therapy. Patient outcome was 
analyzed according the ASTRO criteria. Furthermore PSA 
nadir and PSA bouncing effects were investigated. 
Patients risk groups were evaluated as follows: low: 7.5%, 
intermediate: 35%, high: 57.5%. The long-term results were 
evaluated according to Kaplan-Meier. Statistical significance 
was assumed when p 
Results: The mean follow up time was 68 months. The 5- and 
8-year biochemical (BC) control rates according ASTRO were 
67.7/65.5% for all patients. For the risk groups the following 
8 years BC control rates were found: low risk: 100%, 
intermediate risk: 76.7%, high risk: 56.6%. 
BC control for patients with PSA nadir of  
The mean BC disease free survival (5 years) for patients with 
PSA bouncing was 46% and 85.6% without bouncing 
phenomenon. 
 
 
Conclusions: Data of 80 patients were investigated. The 
results fit well into the already published data of our group. 
With PSA bouncing the results were severely deteriorated .  
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Purpose/Objective: To assess the impact of our experience 
with permanent prostate brachytherapy (PBB) along 8 years. 
Materials and Methods: From September 2004 to July 2012, 
247 patients with prostate cancer diagnosis were treated 
with low-dose brachytherapy by real-time planning, 125-I 
loose seeds (SelectSeed model, Isotron lab., Germany), Spot 
Pro planning system (Nucletron/Elekta, Stockholm, Sweden) 
and automatic delivery system (SeedSelectron, 
Nucletron/Elekta, Stockholm, Sweden). Patients were 
chronologically divided into 5 groups: P1 (n=50), P2 (n=50), 
P3 (n=50), P4 (n=50), P5 (n=47). The parameters reported 
were: D90 (dose received by 90% of the prostate volume), 
V100 (prostate volume receiving 100% of the prescribed 
dose), V150, V200, UV150 (for urethra), RV100 (for rectum), 
conformational number (CN), dose homogeneity index (DHI), 
number of needles and seeds and nomogram data. No post-
implant parameters were reported in this study. To analyze 
the procedure treatments time, we rejected 27 cases, in 
which the time increased for external factors, as the 
breakdowns. The 220 remaining implants were divided into 5 
groups of 44 each one. 
Results: We observed a decrease in the time consumed to 
apply this treatment throughout the 8 years (116.1 minutes 
on average), with statistical significance (p<0.001). The 
average D90 was 109.9% with a significant difference among 
the five periods (p<0.001). Similarly, we found significant 
differences for V100 (average 94.1%), V150 (average 59.6%), 
V200 (average 34,1%) and RV100 (average 0.22%). We 
measured a consistent result into nomogram linear data 
adjustment for all PPB treatments (n=220), with a 0.8437 
value for correlation coefficient (R2).  
 
 
 
 
Conclusions: We observed a learning curve for several 
implantation parameters, which led to a meaningful 
suggestion in prostate coverage doses, decrease in rectal 
doses and diminution in the implantation time needed for 
PPB. 
   
PO-1042   
5-year results of HDR brachytherapy, plus radiotherapy 
and ADT for intermediate prostate cancer: a phase II trial 
M. Jolicoeur1, A. Tetreault-Laflamme2, T.V. Nguyen-Huynh1, 
N. Benoit2, J.P. Guay2, B. Fortin3, F. Vincent4, C. Lambert2, F. 
Saad5 
1Hôpital Charles-Le Moyne, Radiation Oncology, Greenfield 
Park, Canada  
2Centre Hospitalier de l'Université de Montreal, Radiation 
Oncology, Montreal, Canada  
3Hopital Maisonneuve-Rosemont, Radiation Oncology, 
Montreal, Canada  
4Centre Hospitalier régional de Trois-Rivières, Radiation 
Oncology, Trois-Rivières, Canada  
5Centre Hospitalier de l'Université de Montreal, Urology, 
Montreal, Canada  
 
Purpose/Objective: To assess the 5-year outcomes of 
patients with intermediate-risk prostate cancer treated with 
hypofractionated external beam radiotherapy (EBRT) and 
high-dose-rate (HDR) brachytherapy boost combined with 
short course androgen deprivation therapy (ADT). 
Materials and Methods: From August 2003 to September 
2007, fifty-one patients with intermediate-risk prostate 
cancer were enrolled in a dose escalation phase II protocol 
(BRP-1 trial) at our institution. Treatment regimen was as 
followed: Six months of ADT, One HDR prostate 
brachytherapy Ir192 was performed under trans-rectal 
ultrasound guidance. Three fractions of 6.5Gy each for a 
total of 19.5Gy were delivered using inverse planning 
technique. Hypofractionated EBRT to 50Gy in 20 fractions 
was delivered to the prostate and proximal seminal vesicles 
and began one week after brachytherapy. Patients were 
assessed every week during treatments, one month post-
treatment and every three to six months thereafter. APS, 
testosterone and complete blood count were taken on each 
visit. The Phoenix biochemical failure (BF) definition was 
used. Gastrointestinal (GI), genitourinary (GU) and sexual 
toxicities were recorded according to the RTOG toxicity 
